Use: Labeled indications
- INDICATIONS AND USAGE Treatment Cefoxitin for Injection, USP is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below.
Full indications and usage US FDA label
INDICATIONS AND USAGE Treatment Cefoxitin for Injection, USP is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections, including pneumonia and lung abscess, caused by Streptococcus pneumoniae, other streptococci (excluding enterococci, e.g., Enterococcus faecalis [formerly Streptococcus faecalis]), Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli, Klebsiella species, Haemophilus influenzae, and Bacteroides species.
(2) Urinary tract infections caused by Escherichia coli, Klebsiella species, Proteus mirabilis, Morganella morganii, Proteus vulgaris and Providencia species (including P. rettgeri). (3) Intra-abdominal infections, including peritonitis and intra-abdominal abscess, caused by Escherichia coli, Klebsiella species, Bacteroides species including Bacteroides fragilis, and Clostridium species.
(4) Gynecological infections, including endometritis, pelvic cellulitis, and pelvic inflammatory disease caused by Escherichia coli, Neisseria gonorrhoeae (including penicillinase-producing strains), Bacteroides species including B. fragilis, Clostridium species, Peptococcus niger, Peptostreptococcus species, and Streptococcus agalactiae. Cefoxitin for Injection, USP, like cephalosporins, has no activity against Chlamydia trachomatis.
Therefore, when Cefoxitin for Injection, USP is used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (5) Septicemia caused by Streptococcus pneumoniae, Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli, Klebsiella species, and Bacteroides species including B. fragilis.
(6) Bone and joint infections caused by Staphylococcus aureus (including penicillinase-producing strains). (7) Skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains), Staphylococcus epidermidis, Streptococcus pyogenes and other streptococci (excluding enterococci e.g., Enterococcus faecalis [formerly Streptococcus faecalis]), Escherichia coli, Proteus mirabilis, Klebsiella species, Bacteroides species including B. fragilis, Clostridium species, Peptococcus niger, and Peptostreptococcus species.
Appropriate culture and susceptibility studies should be performed to determine the susceptibility of the causative organisms to Cefoxitin for Injection, USP. Therapy may be started while awaiting the results of these studies. In randomized comparative studies, Cefoxitin for Injection, USP and cephalothin were comparably safe and effective in the management of infections caused by gram-positive cocci and gram-negative rods susceptible to the cephalosporins.
Cefoxitin for Injection, USP has a high degree of stability in the presence of bacterial beta-lactamases, both penicillinases and cephalosporinases. Many infections caused by aerobic and anaerobic gram-negative bacteria resistant to some cephalosporins respond to Cefoxitin for Injection, USP. Similarly, many infections caused by aerobic and anaerobic bacteria resistant to some penicillin antibiotics (ampicillin, carbenicillin, penicillin G) respond to treatment with Cefoxitin for Injection, USP.
Many infections caused by mixtures of susceptible aerobic and anaerobic bacteria respond to treatment with Cefoxitin for Injection, USP. Prevention Cefoxitin for Injection, USP is indicated for the prophylaxis of infection in patients undergoing uncontaminated gastrointestinal surgery, vaginal hysterectomy, abdominal hysterectomy, or cesarean section.
If there are signs of infection, specimens for culture should be obtained for identification of the causative organism so that appropriate treatment may be instituted. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefoxitin for Injection, USP and other antibacterial drugs, Cefoxitin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.
When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Contraindications
CONTRAINDICATIONS Cefoxitin for Injection is contraindicated in patients who have shown hypersensitivity to cefoxitin and the cephalosporin group of antibiotics.
US FDA labelDosing: Adult
Dosage and administration (US label) US FDA label
DOSAGE AND ADMINISTRATION Treatment Adults The usual adult dosage range is 1 gram to 2 grams every 6 to 8 hours. Dosage should be determined by susceptibility of the causative organisms, severity of infection, and the condition of the patient (see Table 1 for dosage guidelines). If C. trachomatis is a suspected pathogen, appropriate anti-chlamydial coverage should be added, because cefoxitin sodium has no activity against this organism.
Cefoxitin for Injection may be used in patients with reduced renal function with the following dosage adjustments: In adults with renal insufficiency, an initial loading dose of 1 gram to 2 grams may be given. After a loading dose, the recommendations for maintenance dosage (Table 2) may be used as a guide. When only the serum creatinine level is available, the following formula (based on sex, weight, and age of the patient) may be used to convert this value into creatinine clearance.
The serum creatinine should represent a steady state of renal function. Males: Weight (kg) x (140-age) 72 x serum creatinine (mg/100 mL) Females: 0.85 x above value In patients undergoing hemodialysis, the loading dose of 1gram to 2 grams should be given after each hemodialysis, and the maintenance dose should be given as indicated in Table 2.
Antibiotic therapy for group A beta-hemolytic streptococcal infections should be maintained for at least 10 days to guard against the risk of rheumatic fever or glomerulonephritis. In staphylococcal and other infections involving a collection of pus, surgical drainage should be carried out where indicated. Pediatric Patients The recommended dosage in pediatric patients 3 months of age and older is 80 to 160 mg/kg of body weight per day divided into four to six equal doses.
The higher dosages should be used for more severe or serious infections. The total daily dosage should not exceed 12 grams. At this time no recommendation is made for pediatric patients from birth to 3 months of age (see PRECAUTIONS). In pediatric patients with renal insufficiency, the dosage and frequency of dosage should be modified consistent with the recommendations for adults (see Table 2).
Prevention Effective prophylactic use depends on the time of administration. Cefoxitin for Injection usually should be given one-half to one hour before the operation, which is sufficient time to achieve effective levels in the wound during the procedure. Prophylactic administration should usually be stopped within 24 hours since continuing administration of any antibiotic increases the possibility of adverse reactions but, in the majority of surgical procedures, does not reduce the incidence of subsequent infection.
For prophylactic use in uncontaminated gastrointestinal surgery, vaginal hysterectomy, or abdominal hysterectomy, the following doses are recommended: Adults: 2 grams administered intravenously just prior to surgery (approximately one-half to one hour before the initial incision) followed by 2 grams every 6 hours after the first dose for no more than 24 hours. Pediatric Patients (3 months and older): 30 to 40 mg/kg doses may be given at the times designated above.
Cesarean Section Patients: For patients undergoing cesarean section, either a single 2 gram dose administered intravenously as soon as the umbilical cord is clamped OR a 3-dose regimen consisting of 2 grams given intravenously as soon as the umbilical cord is clamped followed by 2 grams 4 and 8 hours after the initial dose is recommended. (See CLINICAL STUDIES.) Table 1.
Guidelines for Dosage of Cefoxitin for Injection Type of Infection Daily Dosage Frequency and Route Uncomplicated forms* of infections such as pneumonia, urinary tract infection, cutaneous infection 3 to 4 grams 1 gram every 6 to 8 hours IV Moderately severe or severe infections 6 to 8 grams 1 gram every 4 hours or 2 grams every 6 to 8 hours IV Infections commonly needing antibiotics in higher dosage (e.g., gas gangrene) 12 grams 2 grams every 4 hours or 3 grams every 6 hours IV *Including patients in whom bacteremia is absent or unlikely. Table 2.
Maintenance Dosage of Cefoxitin for Injection in Adults with Reduced Renal Function Renal Function Creatinine Clearance (mL/min) Dose (Grams) Frequency Mild impairment 50 to 30 1 to 2 Every 8 to 12 hours Moderate impairment 29 to 10 1 to 2 Every 12 to 24 hours Severe impairment 9 to 5 0.5 to 1 Every 12 to 24 hours Essentially no function < 5 0.5 to 1 Every 24 to 48 hours Table 3. Preparation of Solution for Intravenous Administration Strength Amount of Diluent to be Added (mL)** Approximate Withdrawable Volume (mL) Approximate Average Concentration (mg/mL) 1 gram Vial 10 10.5 95 2 gram Vial 10 or 20 11.1 or 21 180 or 95 **Shake to dissolve and let stand until clear.
Preparation of Solution Table 3 is provided for convenience in constituting Cefoxitin for Injection for intravenous administration. For Vials One gram should be constituted with at least 10 mL, and 2 grams with 10 mL or 20 mL, of Sterile Water for Injection, Bacteriostatic Water for Injection, 0.9 percent Sodium Chloride Injection, or 5 percent Dextrose Injection.
These primary solutions may be further diluted in 50 mL to 1000 mL of the diluents listed under the Vials portion of the Compatibility and Stability section. Benzyl alcohol as a preservative has been associated with toxicity in neonates. While toxicity has not been demonstrated in pediatric patients greater than 3 months of age, in whom use of Cefoxitin for Injection may be indicated, small pediatric patients in this age range may also be at risk for benzyl alcohol toxicity.
Therefore, diluent containing benzyl alcohol should not be used when Cefoxitin for Injection is constituted for administration to pediatric patients in this age range. Administration Cefoxitin for Injection may be administered intravenously after constitution. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.
Intravenous Administration The intravenous route is preferable for patients with bacteremia, bacterial septicemia, or other severe or life threatening infections, or for patients who may be poor risks because of lowered resistance resulting from such debilitating conditions as malnutrition, trauma, surgery, diabetes, heart failure, or malignancy, particularly if shock is present or impending. For intermittent intravenous administration, a solution containing 1 gram or 2 grams in 10 mL of Sterile Water for Injection can be injected over a period of 3 to 5 minutes.
Using an infusion system, it may also be given over a longer period of time through the tubing system by which the patient may be receiving other intravenous solutions. However, during infusion of the solution containing Cefoxitin for Injection, it is advisable to temporarily discontinue administration of any other solutions at the same site.
For the administration of higher doses by continuous intravenous infusion, a solution of Cefoxitin for Injection may be added to an intravenous bottle containing 5 percent Dextrose Injection, 0.9 percent Sodium Chloride Injection, or 5 percent Dextrose and 0.9 percent Sodium Chloride Injection. BUTTERFLY ®†† or scalp vein-type needles are preferred for this type of infusion.
Solutions of Cefoxitin for Injection, like those of most beta-lactam antibiotics, should not be added to aminoglycoside solutions (e.g., gentamicin sulfate, tobramycin sulfate, amikacin sulfate) because of potential interaction. However, Cefoxitin for Injection and aminoglycosides may be administered separately to the same patient.
Compatibility and Stability Vials Cefoxitin for Injection, as supplied in vials and constituted to 1 gram/10 mL with Sterile Water for Injection, Bacteriostatic Water for Injection, (see Preparation of Solution), 0.9 percent Sodium Chloride Injection, or 5 percent Dextrose Injection, maintains satisfactory potency for 6 hours at room temperature or for one week under refrigeration (below 5ºC). These primary solutions may be further diluted in 50 mL to 1000 mL of the following diluents and maintain potency for an additional 18 hours at room temperature or an additional 48 hours under refrigeration: 0.9 percent Sodium Chloride Injection 5 percent or 10 percent Dextrose Injection 5 percent Dextrose and 0.9 percent Sodium Chloride Injection 5 percent Dextrose Injection with 0.2 percent or 0.45 percent saline solution Lactated Ringer’s Injection 5 percent Dextrose in Lactated Ringer’s Injection 5 percent Sodium Bicarbonate Injection M/6 sodium lactate solution Mannitol 5% and 10% After the periods mentioned above, any unused solutions should be discarded.
Dosing: Altered kidney function
Cefoxitin for Injection may be used in patients with reduced renal function with the following dosage adjustments: In adults with renal insufficiency, an initial loading dose of 1 gram to 2 grams may be given.
When only the serum creatinine level is available, the following formula (based on sex, weight, and age of the patient) may be used to convert this value into creatinine clearance.
The serum creatinine should represent a steady state of renal function.
Males: Weight (kg) x (140-age) 72 x serum creatinine (mg/100 mL) Females: 0.85 x above value In patients undergoing hemodialysis , the loading dose of 1gram to 2 grams should be given after each hemodialysis, and the maintenance dose should be given as indicated in Table 2.
In pediatric patients with renal insufficiency, the dosage and frequency of dosage should be modified consistent with the recommendations for adults (see Table 2).
Maintenance Dosage of Cefoxitin for Injection in Adults with Reduced Renal Function Renal Function Creatinine Clearance (mL/min) Dose (Grams) Frequency Mild impairment 50 to 30 1 to 2 Every 8 to 12 hours Moderate impairment 29 to 10 1 to 2 Every 12 to 24 hours Severe impairment 9 to 5 0.5 to 1 Every 12 to 24 hours Essentially no function < 5 0.5 to 1 Every 24 to 48 hours Table 3.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Pediatric
Pediatric use (US label) US FDA label
Pediatric Use Safety and efficacy in pediatric patients from birth to 3 months of age have not yet been established. In pediatric patients 3 months of age and older, higher doses of Cefoxitin for Injection have been associated with an increased incidence of eosinophilia and elevated SGOT.
Dosing: Older adult
Geriatric use (US label) US FDA label
Geriatric Use Of the 1,775 subjects who received cefoxitin in clinical studies, 424 (24%) were 65 and over, while 124 (7%) were 75 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out (see CLINICAL PHARMACOLOGY).
This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function (see DOSAGE AND ADMINISTRATION and PRECAUTIONS).
Dosage forms
Philippines
- Powder for injection: 1 g
- Powder for solution for injection: 1 g
- Cefoxitin sodium) powder for injection: 1 g (equivalent to 1.065 g
- Dry powder for injection: 1 mg/vial
- Sterile powder for injection: 1 g
Registered products in the Philippines
55 products registered with the Food and Drug Administration (FDA) Philippines list Cefoxitin as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products55
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AcefoxinCefoxitin (as sodium) | 1 g Powder for Injection (IM/IV)20 mL-capacity USP type III clear glass vial rubber stopper aluminum seal (Box of 1's) | Rx | Makcur Laboratories LimitedIndia | One Aceso Pharmaceuticals Inc.Importer: Afree Pharmaceutical Distribution Corp. | DRP-14008-02 | Jun 5, 2028 | |
AcifoxCefoxitin (as sodium) | 1 g Powder for Solution for Injection (I.M./I.V.)Type III Clear and Colorless Glass Vial with Butyl Rubber Stopper and Flip-Off Cap (Box of 1’s and 10's) | Rx | NCPC Hebei Huamin Pharmaceutical Co., Ltd.China | Aglobal Care, Inc | DRP-11382 | Nov 25, 2030 | |
AefoxCefoxitin sodium | 1g Powder for Injection (IM/IV)10mL USP Type I clear glass vial with grey bromobutyl rubber stopper and aluminum seal with yellow plastic flip-off cap (Box of 10's) | Rx | Swiss Pharmaceutical Co., Ltd.Taiwan | Dynasty Pharmaceuticals | DR-XY47528 | Nov 12, 2031 | |
AlfoxinCefoxitin (as sodium) | 1 g Powder for Injection (IM/IV)Clear Glass USP Type I Vial (Box of 1's) | Rx | Korea United Pharm. Inc.Republic of Korea | Altomed Pharmaceuticals, Inc. | DR-XY32622 | Nov 17, 2031 | |
AmsowelCefoxitin (as sodium) | 1g Powder for Injection (IM/IV)USP Type II Modular Vial x 10mL (Box of 1's) | Rx | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.China | Amson PharmaceuticalsImporter: Sahar International Trading, Inc. | DRP-6501-01 | Sep 19, 2027 | |
BlesofoxitinCefoxitin (as sodium) | 1g Powder For Injection (IM/IV)20 mL-capacity USP type III clear glass vial rubber stopper aluminum seal (Box of 1's) | Rx | Makcur Laboratories LimitedIndia | Afree Pharmaceutical Distribution Corp. | DRP-14008 | Jun 5, 2028 | |
BrofoxinCefoxitin (as Sodium) | 1 g Powder for Injection (IM/IV)USP Type I clear glass vial stopped with grey color chlorobutyl rubber stopper and sealed with green aluminum cap (Box of 10's) | Rx | Union Korea Pharm. Co., Ltd.Republic of Korea | JustRight Healthcare Inc.Importer: H & B Pharma International Inc. | DRP-5600-09 | Oct 15, 2029 | |
CefohabCefoxitin (as Sodium) | 1 g Powder for Injection (I.M./I.V.)USP Type I clear glass vial stopped with grey color chlorobutyl rubber stopper and sealed with green aluminum cap Box of 10's | Rx | Union Korea Pharm Co., Ltd.Republic of Korea | Pharmaessence Inc.Importer: H & B Pharma International Inc. | DRP-5600-07 | Oct 15, 2029 | |
CefosenzCefoxitin (as Sodium) | 1 g Powder for Injection (IM/IV)USP Type I clear glass vial stopped with grey color chlorobutyl rubber stopper and sealed with green aluminium cap (Box of 10's) | Rx | Union Korea Pharm. Co., Ltd.South Korea | Uni-Pharma Phils. Inc.Importer: H & B Pharma International Inc. | DRP-5600-03 | Oct 15, 2029 | |
CefovexCefoxitin (as sodium) | 1g Powder for InjectionType I Clear and Colorless Glass Vial + 10 mL Diluent (Sterile Water for Injection) in Type I amber glass ampoule per box Box of 1's | Rx | North China Pharmaceutical Co., LtdChina | Sannovex Pharmaceutical Distributor | DRP-6531 | Feb 16, 2031 | |
CefoxidCefoxitin (as sodium) | 1g Powder for Injection (IM/IV)USP Type II Modular Vial x 10 mL (Box of 1's) | Rx | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.China | Dynasty PharmaceuticalsImporter: Sahar International Trading, Inc. | DRP-6501 | Sep 19, 2027 | |
CefoxiGetCefoxitin (as sodium) | 1 g Powder for Solution for Injection (IM/IV)USP Type I Glass Vial x 20 mL (Box of 1) | Rx | Swiss Parenterals Ltd.India | 2MG Incorporated | DRP-15509 | Jul 30, 2029 | |
CefoxisanCefoxitin (as sodium) | 1g Powder for Injection (IM/IV)20 mL USP Type I glass vial with rubber stopper and yellow alu / plastic flip-off seal (Box of 1's) | Rx | Swiss Parenterals Ltd.India | Compharm, Inc.Importer: Sanimed Pharmaceuticals Inc. | DRP-15157-01 | May 15, 2029 | |
CefoxitCefoxitin (As Sodium) | 1 g Powder for Injection (IM/IV)10 mL-capacity USP Type II glass vial (Box of 1’s) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Pharmakon Biotec Inc. | DRP-11605 | Apr 6, 2027 | |
CefoxsaphCefoxitin (As Sodium) | 1 g Powder For InjectionUSP Type I clear glass vial with grey bromobutyl rubber stopper and aluminum royal blue flip-off seal (Box of 1's and 10's) | Rx | Kilitch Drugs (India) Ltd.India | Nelpa Lifesciences, Inc. | DRP-13045 | Nov 22, 2027 | |
CefoxyCefoxitin (as sodium) | 1 g Powder for Injection (IV)Type II Colorless Glass Mould Vial with Gray Halogenated Butyl Rubber Stopper and Blue Aluminum Plastic Cap x 1's (Box of 1's and 10's) (In a box of 10's - vials are individually packed in a carton) | Rx | Reyoung Pharmaceutical Co., Ltd.China | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambicare Pharmaceuticals, Inc. | DRP-11374-02 | Mar 7, 2032 | |
CeftinCefoxitin sodium | 1 g Powder for Injection (IM/IV)Type I Clear Glass Vial with rubber stopper and blue flip off seal (Box of 10’s) | Rx | Samjin Pharmaceutical Co., Ltd.Republic of Korea | Apothecon Drug Int’l Corp.Importer: Medbridge, Inc. | DRP-2400-02 | Oct 5, 2027 | |
CoxtinCefoxitin (as Sodium) | 1 g Powder for Injection (IM/IV)USP Type I clear glass vial stopped with grey color chlorobutyl rubber stopper and sealed with green aluminium cap (Box of 10's) | Rx | Union Korea Pharm. Co., Ltd.South Korea | Medhaus Pharma, IncorporatedImporter: H & B Pharma International Inc. | DRP-5600-04 | Oct 15, 2029 | |
DeceftinCefoxitin (as Sodium) | 1 g Powder For Injection (I.M./I.V.)USP Type I glass vial sealed with 20 mm grey bromo butyl rubber stopper and 20 mm yellow flip-off aluminum Seal (Box of 1's) | Rx | Swiss Parenterals Ltd.India | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International CorporationTrader: BioRx Pharma Labs LLP | DRP-9072-01 | Jul 20, 2031 | |
FixotinCefoxitin | 1 g (equivalent to 1.065 g Cefoxitin Sodium) Powder for Injection (IM/IV)Plain Glass Vial (USP Type-I) x 20 mL with Flip-off Seal and Grey Butyl Rubber Stopper (Box of 1's) | Rx | Swiss Parenterals Ltd.India | Applied Pharmaceutical Distribution, Inc. | DRP-11658 | Mar 16, 2031 | |
FoxiCefoxitin (as sodium) | 1 g Powder for Injection (I.M/I.V.)USP Type I Clear Glass Vial + 10 mL Diluent (Box of 1's) | Rx | Phil Inter Pharma Co., Ltd.Vietnam | Multigro Healthcare Inc.Importer: Grovic Pharma Inc. | DRP-5682-03 | Nov 5, 2029 | |
FOXIDECefoxitin (as sodium) | 1 g Powder for Injection (IM/IV)10 mL-Capacity USP Type II glass vial (Box of 1's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Pharma King DistributorImporter: Pharmakon Biotec Inc. | DRP-11605-01 | Apr 6, 2027 | |
FoxilevCefoxitin (as sodium) | 1 g Powder for Injection (IM/IV)20 mL capacity USP Type III clear glass vial rubber stopper aluminum seal (Box of 1's) | Rx | Makcur Laboratories LimitedIndia | HLM Pharmaceutical Inc.Importer: Afree Pharmaceutical Distribution Corp. | DRP-14008-01 | Jun 5, 2028 | |
FoxinCefoxitin (as Sodium) | 1g Powder for Solution for Injection (IM/IV)Type III glass vial (Box of 1) | Rx | Haikou Pharmaceutical Factory Co. Ltd.China | Endure Medical, Inc. | DRP-16847 | Jul 4, 2031 | |
FoxistarCefoxitin | 1 mg/vial Dry Powder For Injection (IM/IV)Type III Clear Glass Vial with Bromobutyl Rubber Stopper and Aluminum Flip-off Seal x 10 mL (Box of 1's) | Rx | Inject Care Parenterals Pvt. Ltd.India | Pharmastar Int'l Trading Corp. | DRP-18309 | Jun 9, 2031 | |
FoxitinCefoxitin (as sodium) | 1 g Powder for Injection20 mL USP Type I Glass Vial Green Flip-Off Cap with Logo (Box of 1's and 10's) | Rx | Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd.China | PharmAsia-Cuvest, Incorporated | DR-XY39850 | Aug 9, 2031 | |
FoxsenzCefoxitin (as Sodium) | 1 g Powder for Injection (IM/IV)USP Type I clear glass vial stopped with grey color chlorobutyl rubber stopper and sealed with green aluminium cap Box of 10's | Rx | Union Korea Pharm Co., Ltd.Republic of Korea | Medirich Pharma Distribution Corp.Importer: H & B Pharma International Inc. | DRP-5600-06 | Oct 15, 2029 | |
GoxitinCefoxitin (as sodium) | 1 g Powder for Injection (IV)Type II Colorless Glass Mould Vial with Gray Halogenated Butyl Rubber Stopper and Blue Aluminum Plastic Cap x 1's (Box of 10's) | Rx | Reyoung Pharmaceutical Co. Ltd.China | Applied Pharmaceutical Distribution Inc.Importer: Ambicare Pharmaceuticals Inc. | DRP-11374-01 | Mar 7, 2032 | |
GroxitinCefoxitin (as sodium) | 1 g Powder for Injection (I.M./I.V.)USP Type I Clear Glass Vial + 10 mL Diluent Box of 1's | Rx | PHIL INTER PHARMA CO., LTD. (PLANT 2)Vietnam | GROVIC PHARMA INC. | DRP-5682 | Nov 5, 2029 | |
HaxotinCefoxitin (as Sodium) | 1g Powder for Injection (I.M./I.V.)USP Type I clear glass vial with rubber stopper and blue flip-off seal in individual box (Box of 10's) | Rx | Harbin Pharmaceutical Group Co., Ltd. General Pharm. FactoryChina | Endure Medical, Inc. | DR-XY34181 | Jan 30, 2028 | |
HaxotinCefoxitin (as Sodium) | 1g Powder for Injection (I.M./I.V.)USP Type I clear glass vial rubber stopper and blue flip-off seal in individual box (Box of 10's) | Rx | Harbin Pharmaceutical Group Co., Ltd. General Pharm. FactoryChina | Endure Medical, Inc. | DRP-16750 | Jan 30, 2028 | |
MonowelCefoxitin (as sodium) | 1 g Sterile Powder for Injection (I.M./ I.V.)Type I Glass Vial with rubber stopper and orange flip off seal x 1 g (Box of 1's) | Rx | Biolab Co., Ltd.Thailand | The Cathay Drug Co., Inc. | DR-XY27927 | Oct 9, 2027 | |
One-CefoxcelCefoxitin (As Sodium) | 1 g Powder for Injection (IV)20 mL-capacity USP Type I Glass vial with grey bromobutyl rubber stopper and aluminum flip-off seal (Box of 1’s) | Rx | Swiss Parenterals Ltd.India | One Dexcel Pharma Inc. | DRP-12150 | Jun 22, 2027 | |
OximedCefoxitin sodium | 1 g Powder for Injection (IM/IV)Type I Clear Glass Vial with rubber stopper and blue flip-off seal (Box of 10's) | Rx | Samjin Pharmaceutical Co., LtdRepublic of Korea | Medbridge Inc. | DRP-2400 | Oct 5, 2027 | |
PacetinCefoxitin sodium | 1 g Powder for Injection (IM/IV)Type I Clear Glass Vial with rubber stopper and blue flip off seal x 1's (Box of 10’s) | Rx | Samjin Pharmaceutical Co., Ltd.Republic of Korea | Unimex, Inc.Importer: Medbridge Inc. | DRP-2400-05 | Oct 5, 2027 | |
PillcefoxCefoxitin (as sodium) | 1 g Powder for Injection (IV)Type II Colorless Glass Mould Vial with Gray Halogenated Butyl Rubber Stopper and Blue Aluminum Plastic Cap x 1's (Box of 10's) | Rx | Reyoung Pharmaceutical Co., LtdChina | Diafarm Inc.Importer: Ambicare Pharmaceuticals Inc. | DRP-11374-03 | Mar 7, 2032 | |
PlaxitinCefoxitin (as sodium) | 1 g Powder for Injection (I.M./I.V.)USP Type I Clear Glass Vial + 10 mL Diluent (Box of 1's) | Rx | PHIL INTER PHARMA CO., LTD. (PLANT 2)Vietnam | SEA-King Pharma Inc.Importer: GROVIC PHARMA INC. | DRP-5682-02 | Nov 5, 2029 | |
RemosepCefoxitin (as sodium) | 1 g Powder for Injection (IM/IV)10 mL Capacity USP Type III Clear and Colorless Glass Vial with Grey Butyl Rubber Stopper and Flip-off Seal (Box of 1's) | Rx | Sance Laboratories Pvt. Ltd.India | UNILAB, Inc.Importer: Pharmakon Biotec Inc. | DRP-8650-01 | Jan 24, 2030 | |
San-XitinCefoxitin (as sodium) | 1 g Powder for Injection (IM/IV)10 mL Capacity USP Type III Clear and Colorless Glass Vial with Grey Butyl Rubber Stopper and Flip-off Seal (Box of 1's) | Rx | Sance Laboratories Pvt. Ltd.India | Pharmakon Biotec Inc. | DRP-8650 | Jan 24, 2030 | |
Sanoxin-1000Cefoxitin (as sodium) | 1 g Powder for Injection (I.M./I.V.)USP Type III clear glass vial with butyl rubber stopper and flip off seal (Box of 1’s) | Rx | Sance Laboratories Pvt. Ltd.India | AMB HK Enterprises Inc. | DRP-8377 | Sep 18, 2029 | |
SeaxitinCefoxitin (as sodium) | 1 g Powder for Injection (I.M./I.V.)USP Type I Clear Glass Vial + 10 mL Diluent Box of 1's | Rx | Phil Inter Pharma Co., Ltd.Vietnam | Central West Medicale, Inc.Importer: Grovic Pharma inc. | DRP-5682-01 | Nov 5, 2029 | |
SefozinCefoxitin (as sodium) | 1 g Powder for Injection (IM/IV)10 mL-capacity Borosilicate Glass Bottle with chlorobutyl rubber plug and Alu-plastic cap (Box of 1's) | Rx | Yangtze River Pharmaceutical (Group) Co., Ltd.China | Aglobal Care Inc.Importer: Aglobal Care, Inc. | DRP-15461 | Jul 11, 2029 | |
TrefoxinCefoxitin (as sodium) | 1g Powder for Injection (I.M./I.V.)USP Type III clear glass vial stoppered with 20mm grey bromobutyl rubber stopper, sealed with 20mm aluminum and blue flip-off seal (Box of 1's) | Rx | Sance Laboratories Pvt.Ltd.India | Teramedix Pharma Trading Inc. | DR-XY47620 | Dec 20, 2026 | |
TrexinCefoxitin (as sodium) | 1 g Powder for Injection (IV)10 mL-capacity USP type III clear glass vial with rubber stopper and aluminum sky blue flip-off seal (Box of 1's) | Rx | Vellinton HealthcareIndia | Pranish Inc. | DR-XY48914 | Nov 9, 2028 | |
TrexinCefoxitin (as sodium) | 1 g Powder for Injection (IV)10 mL-capacity USP type III clear glass vial with rubber stopper and aluminum sky blue flip-off seal (Box of 1's) | Rx | Vellinton HealthcareIndia | Pranish Inc. | DRP-14991 | Nov 9, 2028 | |
TriaxinCefoxitin (as Sodium) | 1 g Powder for Injection (IM/IV)USP Type I clear glass vial stopped with grey color chlorobutyl rubber stopper and sealed with green aluminium cap (Box of 10's) | Rx | Union Korea Pharm Co., Ltd.Republic of Korea | GPC Geo Pharma CorporationImporter: H & B Pharma International Inc. | DRP-5600-02 | Oct 15, 2029 | |
XifoxCefoxitin sodium | 1 g Powder for Injection (IM/IV)Type I Clear Glass Vial with rubber stopper and blue flip-off seal x 1’s (Box of 10’s) | Rx | Samjin Pharmaceutical Co., Ltd.Republic of Korea | Medhaus Pharma, IncorporatedImporter: Medbridge Inc. | DRP-2400-04 | Oct 5, 2027 | |
XitinCefoxitin (as Sodium) | 1 g Powder For Injection (I.M./I.V.)USP Type I glass vial sealed with 20 mm grey bromo butyl rubber stopper and 20 mm yellow flip-off aluminum Seal (Box of 1's) | Rx | Swiss Parenterals Ltd.India | Ambica International CorporationTrader: BioRx Pharma Labs LLP | DRP-9072 | Aug 12, 2030 | |
ZengramCefoxitin (as Sodium) | 1 g Powder for Injection (IM/IV)USP Type I clear glass vial stopped with grey color chlorobutyl rubber stopper and sealed with green aluminium cap (Box of 10's) | Rx | Union Korea Pharm. Co., Ltd.Republic of Korea | Pharma King DistributorImporter: H & B Pharma International Inc. | DRP-5600 | Oct 15, 2029 | |
ZepaxCefoxitin (as Sodium) | 1 g Powder for Injection (I.M /I.V)Type I clear and colorless glass vial with yellow flip-off seal (Box of 10's) | Rx | Yoo Young Pharmaceutical Co., LtdRepublic of Korea | Endure Medical, Inc | DR-XY30102 | Oct 7, 2029 | |
ZepaxCefoxitin (as Sodium) | 1 g Powder for Injection (I.M /I.V)Type I clear and colorless glass vial with yellow flip-off seal (Box of 10's) | Rx | YooYoung Pharmaceutical Co., LtdRepublic of Korea | Endure Medical Inc. | DRP-16846 | Oct 7, 2029 | |
ZepotinCefoxitin (as Sodium) | 1 g Powder for Injection (I.M/I.V.)USP Type II Glass Vial with Rubber stopper and Blue Flip-off seal (Box of 10's) | Rx | Singapore Pharmawealth LIfesciences, Inc.Philippines | — | DR-XY35672 | Apr 7, 2029 | |
ZeuxitinCefoxitin (as sodium) | 1 g Powder for Injection (IV)Type II Colorless Glass Mould Vial with Gray Halogenated Butyl Rubber Stopper and Blue Aluminum Plastic Cap x 1's (Box of 1's and 10's) In box of 10's - vials are individually packed in a carton | Rx | Reyoung Pharmaceutical Co. Ltd.China | Ambicare Pharmaceuticals Inc. | DRP-11374 | Mar 7, 2032 | |
(no brand name)Cefoxitin sodium | 1 g Powder for Injection (IM/IV)USP type I glass vial with rubber stopper and aluminum flip-off cap (Box of 10's) | Rx | Phil Inter Pharma Co., Ltd. (Plant 2)Vietnam | Bliss Pharma Distribution and Consultancy Corp. | DR-XY49393 | May 13, 2030 | |
(no brand name)Cefoxitin (as sodium) | 1 g Powder for Injection (IM/IV)20 mL USP type I glass vial with rubber stopper and yellow alu/plastic flip-off seal (Box of 1's) | Rx | Swiss Parenterals Ltd.India | Sanimed Pharmaceuticals Inc. | DRP-15157 | May 15, 2029 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Warnings/Precautions
Warnings and precautions (US label) US FDA label
WARNINGS BEFORE THERAPY WITH CEFOXITIN FOR INJECTION IS INSTITUTED, CAREFUL INQUIRY SHOULD BE MADE TO DETERMINE WHETHER THE PATIENT HAS HAD PREVIOUS HYPERSENSITIVITY REACTIONS TO CEFOXITIN, CEPHALOSPORINS, PENICILLINS, OR OTHER DRUGS. THIS PRODUCT SHOULD BE GIVEN WITH CAUTION TO PENICILLIN-SENSITIVE PATIENTS. ANTIBIOTICS SHOULD BE ADMINISTERED WITH CAUTION TO ANY PATIENT WHO HAS DEMONSTRATED SOME FORM OF ALLERGY, PARTICULARLY TO DRUGS.
IF AN ALLERGIC REACTION TO CEFOXITIN FOR INJECTION OCCURS, DISCONTINUE THE DRUG. SERIOUS HYPERSENSITIVITY REACTIONS MAY REQUIRE EPINEPHRINE AND OTHER EMERGENCY MEASURES. Clostridium difficile associated diarrhea (CDAD) has been reported with the use of nearly all antibacterial agents, including cefoxitin, and may range in severity from mild diarrhea to fatal colitis.
Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile. C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy.
CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.
Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.
Drug interactions
Drug interactions (US label) US FDA label
Drug Interactions Increased nephrotoxicity has been reported following concomitant administration of cephalosporins and aminoglycoside antibiotics.
Adverse reactions
Adverse reactions (US label) US FDA label
ADVERSE REACTIONS Cefoxitin for Injection is generally well tolerated. The most common adverse reactions have been local reactions following intravenous injection. Other adverse reactions have been encountered infrequently. Local Reactions Thrombophlebitis has occurred with intravenous administration. Allergic Reactions Rash (including exfoliative dermatitis and toxic epidermal necrolysis), urticaria, flushing, pruritus, eosinophilia, fever, dyspnea, and other allergic reactions including anaphylaxis, interstitial nephritis and angioedema have been noted.
Cardiovascular Hypotension. Gastrointestinal Diarrhea, including documented pseudomembranous colitis which can appear during or after antibiotic treatment. Nausea and vomiting have been reported rarely. Neuromuscular Possible exacerbation of myasthenia gravis. Blood Eosinophilia, leukopenia including granulocytopenia, neutropenia, anemia, including hemolytic anemia, thrombocytopenia, and bone marrow depression.
A positive direct Coombs test may develop in some individuals, especially those with azotemia. Liver Function Transient elevations in SGOT, SGPT, serum LDH, and serum alkaline phosphatase; and jaundice have been reported. Renal Function Elevations in serum creatinine and/or blood urea nitrogen levels have been observed. As with the cephalosporins, acute renal failure has been reported rarely.
The role of Cefoxitin for Injection in changes in renal function tests is difficult to assess, since factors predisposing to prerenal azotemia or to impaired renal function usually have been present. In addition to the adverse reactions listed above which have been observed in patients treated with Cefoxitin for Injection, the following adverse reactions and altered laboratory test results have been reported for cephalosporin class antibiotics: Urticaria, erythema multiforme, Stevens-Johnson syndrome, serum sickness-like reactions, abdominal pain, colitis, renal dysfunction, toxic nephropathy, false-positive test for urinary glucose, hepatic dysfunction including cholestasis, elevated bilirubin, aplastic anemia, hemorrhage, prolonged prothrombin time, pancytopenia, agranulocytosis, superinfection, vaginitis including vaginal candidiasis.
Several cephalosporins have been implicated in triggering seizures, particularly in patients with renal impairment when the dosage was not reduced. (See DOSAGE AND ADMINISTRATION). If seizures associated with drug therapy occur, the drug should be discontinued. Anticonvulsant therapy can be given if clinically indicated. To report SUSPECTED ADVERSE EVENTS, contact WG Critical Care, LLC at 1-866-562-4708 or FDA at 1-800-FDA-1088 or www.fda.gov.
Pregnancy considerations
Pregnancy (US label) US FDA label
Pregnancy Reproduction studies performed in rats and mice at parenteral doses of approximately one to seven and one-half times the maximum recommended human dose did not reveal teratogenic or fetal toxic effects, although a slight decrease in fetal weight was observed. There are, however, no adequate and well-controlled studies in pregnant women.
Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. In the rabbit, cefoxitin was associated with a high incidence of abortion and maternal death. This was not considered to be a teratogenic effect but an expected consequence of the rabbit’s unusual sensitivity to antibiotic-induced changes in the population of the microflora of the intestine.
Breastfeeding considerations
Lactation (US label) US FDA label
Nursing Mothers Cefoxitin is excreted in human milk in low concentrations. Caution should be exercised when Cefoxitin for Injection is administered to a nursing woman.
Pharmacokinetics
The half-life after an intravenous dose is 41 to 59 minutes.
Approximately 85 percent of cefoxitin is excreted unchanged by the kidneys over a 6-hour period, resulting in high urinary concentrations.
Probenecid slows tubular excretion and produces higher serum levels and increases the duration of measurable serum concentrations.
In a published study of geriatric patients ranging in age from 64 to 88 years with normal renal function for their age (creatinine clearance ranging from 31.5 to 174.0 mL/min), the half-life for cefoxitin ranged from 51 to 90 minutes, resulting in higher plasma concentrations than in younger adults.
Pharmacokinetics (US label) US FDA label
CLINICAL PHARMACOLOGY Clinical Pharmacology Following an intravenous dose of 1 gram, serum concentrations were 110 mcg/mL at 5 minutes, declining to less than 1 mcg/mL at 4 hours. The half-life after an intravenous dose is 41 to 59 minutes. Approximately 85 percent of cefoxitin is excreted unchanged by the kidneys over a 6-hour period, resulting in high urinary concentrations.
Probenecid slows tubular excretion and produces higher serum levels and increases the duration of measurable serum concentrations. Cefoxitin passes into pleural and joint fluids and is detectable in antibacterial concentrations in bile. In a published study of geriatric patients ranging in age from 64 to 88 years with normal renal function for their age (creatinine clearance ranging from 31.5 to 174.0 mL/min), the half-life for cefoxitin ranged from 51 to 90 minutes, resulting in higher plasma concentrations than in younger adults.
These changes were attributed to decreased renal function associated with the aging process. Microbiology Mechanism of Action Cefoxitin is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. Cefoxitin has activity in the presence of some beta-lactamases, both penicillinases and cephalosporinases, of Gram-negative and Gram-positive bacteria.
Mechanism of Resistance Resistance to cefoxitin is primarily through hydrolysis by beta-lactamase, alteration of penicillin-binding proteins (PBPs), and decreased permeability. Cefoxitin has been shown to be active against most isolates of the following bacteria, both in vitro and in clinical infections as described in the INDICATIONS AND USAGE section: Gram-positive bacteria Staphylococcus aureus (methicillin-susceptible isolates only) Staphylococcus epidermidis (methicillin-susceptible isolates only) Streptococcus agalactiae Streptococcus pneumoniae Streptococcus pyogenes Gram-negative bacteria Escherichia coli Haemophilus influenzae Klebsiella spp.
Morganella morganii Neisseria gonorrhoeae Proteus mirabilis Proteus vulgaris Providencia spp. Anaerobic bacteria Clostridium spp. Peptococcus niger Peptostreptococcus spp. Bacteroides spp. The following in vitro data are available, but their clinical significance is unknown. At least 90 percent of the following microorganisms exhibit an in vitro minimum inhibitory concentration (MIC) less than or equal to the susceptible breakpoint for cefoxitin.
However, the efficacy of cefoxitin in treating clinical infections due to these microorganisms has not been established in adequate and well-controlled clinical trials. Gram-negative bacteria Eikenella corrodens (non-β-lactamase producers) Anaerobic bacteria Clostridium perfringens Prevotella bivia Susceptibility Testing For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC.
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Cefoxitin 1 g Vial | ₱66.95–₱535.00Reference ₱93.48 | per vial | DPRI procurement range |
Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
Formulary and coverage
| Philippine National Formulary | Listed as Cefoxitin |
| PNF listing | Inj.: 1 g vial (IM, IV) (as sodium salt) |
| PNF listing | Inj.: 1g (as sodium) powder for injection with 4% Dextrose Solution for Injection (IV Infusion) |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Cefoxitin · WG Critical Care, LLC [US FDA-approved label, version 8, August 24, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=658a0dc6-6da5-44dc-94f2-1211619297f7
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .